Question 1

What is the catalog number for Tissue FFPE Sections, Cervix?

Accepted Answer

The catalog number for Tissue FFPE Sections, Cervix is CS803232.

Question 2

What sizes are available for Tissue FFPE Sections, Cervix?

Accepted Answer

Tissue FFPE Sections, Cervix is available in the following size(s): 5x 5 µm.

Question 3

Is Tissue FFPE Sections, Cervix in stock?

Accepted Answer

Tissue FFPE Sections, Cervix is currently made to order / not held in immediate stock. Contact us for lead time.

Question 4

Where can I find the safety data sheet (SDS/MSDS) for Tissue FFPE Sections, Cervix?

Accepted Answer

The safety data sheet for Tissue FFPE Sections, Cervix is available here: https://cdn.origene.com/sds/cs803232.pdf.

Question 5

What is Tissue FFPE Sections, Cervix used for?

Accepted Answer

Tissue Sections (5x5um), FFPE; Cervix; Leiomyoma of myometrium

Question 6

Do you offer custom or private-label production of this type of product?

Accepted Answer

Yes, custom antibody development and private-label production services are available. Contact our sales team to discuss your target, timeline, and quantity requirements.

Question 7

What is the immunogen used to generate this antibody?

Accepted Answer

Immunogen or antigen details used to raise this antibody are listed on the product datasheet under immunogen information.

Question 8

What is the recommended positive control for this assay?

Accepted Answer

A recommended positive control, where one is specified by the manufacturer, is listed on the datasheet or in the assay protocol.

Tissue FFPE Sections, Cervix

Product Specifications

Stability

Storage Conditions

Frequently Asked Questions

Explore Other Products

VEGF/VEGFA Monoclonal Antibody

CORO2A Rabbit Polyclonal Antibody

DPP1 (CTSC) (NM_001814) Human Over-expression Lysate

Bone marrow stromal cell antigen 1 (BST1) Mouse Monoclonal Antibody [Clone ID: OTI4E4]

CD71 (TFRC/1149), 0.2mg/mL

Ubiquinol-Cytochrome C Reductase Core Protein I Recombinant Rabbit Monoclonal Antibody [PSH01-23]